Detecting caspase activity in Drosophila larval imaginal discs.

Methods Mol Biol

Department of Cancer Biology, University of Massachusetts Medical School, Worcester, MA, USA.

Published: October 2014

Caspases are a highly specialized class of cell death proteases. Since they are synthesized as inactive full-length zymogens, activation--at least of effector caspases and to some extent also of initiator caspases-requires a proteolytic cleavage event, generating a large and a small subunit, two of each forming the active caspase. The proteolytic cleavage event generates neo-epitopes at both the C-terminus of the large subunit and the N-terminus of the small subunit. The cleaved Caspase-3 (CC3) antibody was raised against the neo-epitope of the large subunit and thus detects only cleaved, but not full-length, Caspase-3. Although raised against human cleaved Caspase-3, the CC3 antibody cross-reacts in other species and detects cleaved caspases, most notably DrICE and Dcp-1, in Drosophila. This protocol describes the procedure for use of the CC3 antibody to detect caspase activity in larval imaginal discs in Drosophila.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4443691PMC
http://dx.doi.org/10.1007/978-1-4939-0357-3_7DOI Listing

Publication Analysis

Top Keywords

cc3 antibody
12
caspase activity
8
larval imaginal
8
imaginal discs
8
proteolytic cleavage
8
cleavage event
8
small subunit
8
large subunit
8
cleaved caspase-3
8
caspase-3 cc3
8

Similar Publications

Targeting CD276 for T cell-based immunotherapy of breast cancer.

J Transl Med

October 2024

Clinical Collaboration Unit Translational Immunology, Department of Internal Medicine, German Cancer Consortium (DKTK), University Hospital Tübingen, Otfried-Müller-Str. 10, 72076, Tübingen, Germany.

Article Synopsis
  • Breast cancer is the most prevalent cancer in women, and while immunotherapy has shown promise, many patients, especially those with triple-negative breast cancer, either aren't eligible for current treatments or don't respond effectively.
  • A study examined tumor samples from 25 breast cancer patients, revealing high levels of CD276, a potential target for new immunotherapies, especially using a novel antibody called CC-3.
  • CC-3 demonstrated significant abilities to activate T cells, promote their growth, and kill tumor cells in lab settings, supporting its potential for further clinical trials in breast cancer patients.
View Article and Find Full Text PDF

The sudden exposure of venous endothelial cells (vECs) to arterial fluid shear stress (FSS) is thought to be a major contributor to coronary artery bypass vein graft failure (VGF). However, the effects of arterial FSS on the vEC secretome are poorly characterised. We propose that analysis of the vEC secretome may reveal potential therapeutic approaches to suppress VGF.

View Article and Find Full Text PDF

Identification of an early biomarker and effective testing device to differentiate dry eye disease secondary to autoimmune disease (Sjögren's syndrome dry eye disease) from non-Sjögren's dry eye disease are prerequisites for appropriate treatment. We aimed to demonstrate the capacity of a new photo-detection device to evaluate tear lactoferrin levels as a tool for differentiating systemic conditions associated with dry eye disease. Patients with non-Sjögren's and Sjögren's syndrome dry eye disease (n = 54 and n = 52, respectively) and controls (n = 11) were enrolled.

View Article and Find Full Text PDF

The bispecific B7H3xCD3 antibody CC-3 induces T cell immunity against bone and soft tissue sarcomas.

Front Immunol

May 2024

Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK); Department of Internal Medicine, University Hospital Tübingen, Tübingen, Germany.

Sarcomas are rare and heterogeneous malignancies that are difficult to treat. Approximately 50% of patients diagnosed with sarcoma develop metastatic disease with so far very limited treatment options. The transmembrane protein B7-H3 reportedly is expressed in various malignancies, including different sarcoma subtypes.

View Article and Find Full Text PDF

Purpose: To evaluate the histopathologic changes and potential correlations of tumor absorbed dose (TAD) after yttrium-90 transarterial radioembolization (TARE) for colorectal liver metastases (CLMs).

Materials And Methods: This prospective pilot study assessed 12 patients with 13 CLMs through positron emission tomography (PET)/computed tomography (CT)-guided biopsies before, immediately after TARE (T0), and 3 weeks after TARE (T3). Subsequent sampling from the same location was enabled by fiducial placement.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!